The authors have observed that the function linking health outcomes with exposure to particulate-matter (PM) follows a biphasic pattern. It peaks around levels of PM10≤100 μg/m3, then weakens and rises again at PM10 levels in the range of hundreds. This could be due to a different nature of PM, the first peak reflecting a stronger anthropogenic and the second - weaker non-anthropogenic particles' effect. The current analysis is focused at the biphasic pattern on the association between PM levels with BG and asthma exacerbations. Pollutants were assessed by local monitoring stations and a satellitebased model. Local weekends/holidays were used to define nonanthropogenic levels of pollutants featured by lower Nitrogen Dioxide, the proxy for anthropogeneity. The association of PM with health outcomes within 24-48h lag was explored using spline functions of generalized additive models. Analysis of 546,420 BG tests (43,569 subjects) showed an almost linear association of PM with asthma with BG during the days with anthropogenic activity and no trend on other days. Analysis of asthmatic exacerbations within 1576 children showed no heterogeneity in association with PM by anthropogeneity levels, possibly indicating a mechanical impact on alveolar as the main trigger for exacerbations rather than PM chemical composition.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chemosphere.2019.124954DOI Listing

Publication Analysis

Top Keywords

health outcomes
8
biphasic pattern
8
levels
5
anthropogenic non-anthropogenic
4
non-anthropogenic particulate
4
particulate matter
4
matter dangerous
4
dangerous differentiate
4
differentiate effects?
4
effects? authors
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: Clinical trial sponsors rely on research sites to identify and enroll appropriate study participants and to correctly and reliably assess symptom severity and function over the course of the trial. Low-recruiting sites represent a large financial and operational burden and may negatively impact trial success either by selecting inappropriate participants and/or high prevalence of data quality issues. We previously reported that >60% of sites in schizophrenia clinical trials recruited ≤5 participants.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.

Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.

Background: In preparation for therapeutic trails involving patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), there is a need for valid, disease-specific caregiver-reported outcome (CRO) measures capable of tracking symptomatic burden in response to therapy over time. CROs are useful tools in clinical trials for individuals with AD, MCI, and dementia who are unable to self-report. In addition, CROs are accepted by the United States Food and Drug Administration to support regulatory claims.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Clinical trials should strive to yield results that are clinically meaningful rather than solely relying on statistical significance. However, the determination of clinical meaningfulness of dementia clinical trials lacks standardization and varies based on the trial's nature. To tackle this issue, a proposed approach involves assessing the time saved before reaching a specific threshold in cognitive status.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!